Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integrated Diagnostics Announces $47M Funding

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
Company raises $30.25 million from the closing of its Series B and $17 million in non-dilutive debt financing provided by Life Sciences Alternative Funding LLC.

The financing round was led by Baird Capital and joined by Indi’s (Integrated Diagnostics') existing investors, InterWest Partners and the Wellcome Trust. Indi’s first product, Xpresys™ Lung, is a breakthrough, molecular diagnostic blood test developed to provide physicians with an objective tool to address a major medical dilemma—the management of indeterminate lung nodules. The mixed equity and debt investment will be used to further commercialize Xpresys, which launched in late 2013, and to develop additional proteomic blood tests using Indi’s technology platform.

“Indi’s Series B represents our investors and management’s belief Xpresys Lung has the potential to achieve blockbuster status,” said Albert A. Luderer, Ph.D., chief executive officer, Indi. “Xpresys Lung was designed to aid physicians in managing lung nodules— helping to eliminate unnecessary invasive procedures on benign conditions; enabling payers to improve outcomes and save millions of dollars in unnecessary procedures; and minimizing patient anxiety. We are very excited to welcome our new backers, Baird Capital and Life Sciences Alternative Funding LLC (LSAF). The partners at both firms have long track records of investing in medical diagnostics companies.”

As part of the financing, Michael Liang, Ph.D., partner with Baird Capital’s venture capital group, joins Indi’s board of directors. Indi also announced that Alexandria Venture Investments, the strategic venture arm of Alexandria Real Estate Equities, Inc., has joined the Series B as an investor.

“We are very pleased to help Indi take their early commercial success with Xpresys Lung to the next level,” said Liang. “Indi has taken their innovative proteomic technology and applied it to a massive unmet need: the high costs associated with over-diagnosing lung nodules. Their strategy is a perfect fit for Baird Capital’s focus on investing in companies who produce innovative technologies that address expanding market needs.”

Data from two studies supporting the technology behind Xpresys Lung were published in Science Translational Medicine on October 16, 2013. Click here to access the full study.

“We believe Xpresys Lung will play a significant role in helping physicians more effectively manage lung nodules—and Indi’s technology for blood-based diagnostics has the potential to become an important tool in multiple areas of health care,” said Steve DeNelsky, president, LSAF. “Our aim is to provide non-dilutive capital to outstanding commercial-stage life sciences companies in medical devices and diagnostics. We are delighted to play a role in Indi’s success.”

Today, it is estimated millions of pulmonary nodules are discovered each year; after traditional assessment protocols, which include biopsies and surgeries, most of these nodules are classified as benign. Xpresys Lung allows for the non-invasive assessment of pulmonary nodules in the 8-30 mm size range; traditionally, nodules of this size are associated with significant diagnostic uncertainty. Xpresys Lung provides physicians with objective information to identify nodules with a high probability of being benign, potentially reducing unnecessary invasive procedures that may be risky for the patient and costly to the healthcare system. In developing the test, researchers at Indi followed an innovative strategy: Xpresys Lung is designed only to assist physicians in identifying lung nodules likely to be benign, and is not intended to assist physicians with the identification of lung cancer.

The blood test measures the relative abundance of proteins from multiple pathways associated with lung cancer, using a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caltech and Integrated Diagnostics Researchers Receive Grand Challenges Point-of-Care Diagnostics Grant
The grant will be issued by Grand Challenges in Global Health, who seeks to engage creative minds across scientific disciplines to work on solutions that could lead to breakthrough advances for those in the developing world.
Monday, December 19, 2011
Integrated Diagnostics Appoints Jay Moyes to Board of Directors
Past CFO of Myriad Genetics joins preeminent team at Dr. Lee Hood-founded molecular diagnostics company.
Thursday, March 10, 2011
Integrated Diagnostics Appoints Dr. Kenneth C. Fang Chief Medical Officer
New CMO to lead rapid development and commercialization of blood-based diagnostics for lung cancer and Alzheimer's disease.
Thursday, January 27, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!